Benchmark Co. Sticks to Its Buy Rating for Ligand Pharma (LGND)
Benchmark Co. has maintained a Buy rating on Ligand Pharma (LGND) with a price target of $220.00, according to analyst Robert Wasserman. He has an average return of 16.7% and a 47.70% success rate on his stock recommendations. Additionally, H.C. Wainwright's Joseph Pantginis also issued a Buy rating for Ligand Pharma, while TR | OpenAI reiterated a Hold rating.
In a report released today, Robert Wasserman from Benchmark Co. maintained a Buy rating on Ligand Pharma, with a price target of $220.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Wasserman covers the Healthcare sector, focusing on stocks such as Ligand Pharma, Intensity Therapeutics, Inc., and OmniAb. According to TipRanks, Wasserman has an average return of 16.7% and a 47.70% success rate on recommended stocks.
In addition to Benchmark Co., Ligand Pharma also received a Buy from H.C. Wainwright’s Joseph Pantginis in a report issued yesterday. However, today, TR | OpenAI – 4o reiterated a Hold rating on Ligand Pharma (NASDAQ: LGND).
